Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Lower ionizable lipid fraction
What ifWhat if the ionizable lipid makes up 50 mol % of the particle and cholesterol fills the released fraction?
Claim language“about 80 mol % of the LNP”
During acidic mixing, the ionizable lipid acquires a positive charge and associates with RNA. Cholesterol packs among the lipid tails and contributes to particle stability after the dispersion is brought to neutral pH.
1.1Permanently charged lipid carrier
What ifWhat if a permanently charged quaternary ammonium lipid binds RNA in a particle that contains no ionizable lipid?
Claim language“a high level of an ionizable lipid”
The quaternary ammonium headgroups associate electrostatically with RNA phosphates during mixing. The cationic lipid pairs with anionic lipids in the endosomal membrane, which promotes membrane rearrangement and RNA release.
1.2Phosphatidylethanolamine as helper lipid
What ifWhat if dioleoylphosphatidylethanolamine serves as the helper phospholipid and the particle contains no phosphatidylcholine?
Claim language“b) phosphatidylcholine”
The two oleoyl chains anchor the phospholipid in the particle. Its compact ethanolamine headgroup favors curved lipid structures that support membrane mixing in the endosome.
1.3Plant sterol as packing agent
What ifWhat if beta-sitosterol fills the sterol fraction and the particle contains no cholesterol?
Claim language“c) cholesterol”
Beta-sitosterol positions its hydroxyl group near the lipid headgroups and its rigid ring system among the lipid tails. This orientation lets it contribute to lipid packing within the particle.
1.4Polysarcosine surface coating
What ifWhat if a polysarcosine chain attached to a lipid anchor provides the surface coating and the particle contains no PEG-lipid?
Claim language“d) PEG-lipid”
The hydrophobic anchor embeds in the particle while the polysarcosine chain extends into water. The hydrated chains create steric repulsion when particles approach, which limits aggregation.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Component substitution
Phosphatidylethanolamine replaces phosphatidylcholine in particles
Dioleoylphosphatidylethanolamine replaces phosphatidylcholine in a blend containing about 80 mol% ionizable lipid, cholesterol and a polyethylene glycol lipid. The lipids are dissolved together in ethanol and mixed with an acidic aqueous phase to form particles. Buffer exchange removes residual ethanol and raises the pH before the particles are added to cultured cardiomyocytes.
Parameter or scale variation
Two particle size ranges for comparison
Two particle batches share an 80:8:10:2 molar ratio of ionizable lipid, phosphatidylcholine, cholesterol and polyethylene glycol lipid. After particle formation and buffer exchange, preparative size-exclusion chromatography separates fractions for hydrodynamic diameter targets of 60–90 nm and 110–150 nm. Dynamic light scattering identifies fractions in each range, and cultured cardiomyocytes receive the pooled fractions at matched total lipid concentrations.
Combination with existing systems
Particle perfusion through a cardiac chip
A microfluidic cardiac culture chip places a perfusion channel alongside a cardiomyocyte chamber separated by a porous membrane. A pump supplies the channel with culture medium containing fluorescently labeled particles composed of about 80 mol% ionizable lipid, phosphatidylcholine, cholesterol and a polyethylene glycol lipid. Time-lapse imaging tracks particle-associated fluorescence in the cardiomyocyte chamber during exposure and after the channel switches to particle-free medium.
Particle uptake on an electrode array
An optically accessible multielectrode array supports a layer of cultured cardiomyocytes. The culture receives fluorescently labeled particles containing about 80 mol% ionizable lipid, phosphatidylcholine, cholesterol and a polyethylene glycol lipid. The array records extracellular field potentials before and after particle exposure, and fluorescence images map particle-associated signal to the regions above the recording electrodes.
Automated or data-driven variant
Automated mixing with particle size feedback
A controller drives separate pumps for an ethanolic blend of about 80 mol% ionizable lipid, phosphatidylcholine, cholesterol and a polyethylene glycol lipid and for an acidic aqueous stream. A microfluidic mixer combines the streams, and an automated sampler dilutes an outlet aliquot for dynamic light scattering. Between runs, the controller uses measured diameter and dispersity to select the next aqueous-to-ethanol flow ratio while holding total flow and lipid composition constant.
Specific version of a part
Tertiary amine lipid at 80 mol %
A lipid with a tertiary amine headgroup and two hydrophobic tails accounts for 80 mol % of total lipid. The headgroup protonates during acidic mixing and associates with RNA phosphates.
Saturated phosphatidylcholine helper lipid
Distearoylphosphatidylcholine supplies a phosphocholine headgroup and two saturated 18-carbon chains. The chains pack with adjacent lipid tails and help maintain particle structure in aqueous dispersion.
Cholesterol in the lipid feed
Free cholesterol dissolves with the other lipid components in the ethanol feed before mixing with the aqueous phase. During particle assembly, its hydroxyl group sits near polar lipid headgroups and its fused rings pack among the hydrophobic tails.
PEG with a dimyristoyl anchor
A PEG chain with a nominal molecular mass of 2,000 daltons attaches to a lipid anchor with two 14-carbon chains. The anchor embeds in the particle and exposes the hydrated PEG chain to the surrounding water.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a) a high level of an ionizable lipid, wherein the ionizable lipid is about 80 mol % of the LNP,
1.2b) phosphatidylcholine,
Belsito, S., Bartucci, R., Montesano, G., Marsh, D., Sportelli, L., Molecular and mesoscopic properties of hydrophilic polymer-grafted phospholipids mixed with phosphatidylcholine in aqueous dispersion: interaction of dipalmitoyl N-poly(ethylene glycol)phosphatidylethanolamine with dipalmitoylphosphatidylcholine studied by spectrophotometry and spin-label electron spin resonance.
A · US 2010/0210575 A1 · ¶
In some implementations, the phospholipid can be selected from the group consisting of egg yolk phosphatidylcholine (EPC), soybean phosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC) egg yolk phosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, and combinations thereof.
B · US 10,123,973 B2 · ¶ 12
1.3c) cholesterol, and
In an embodiment, said sterol is cholesterol (CHOL), thus PEG-DSPE:CHOL:RX.
A · US 2010/0210575 A1 · ¶ 8
Disclosed is a liposomal composition for treatment of cancer, which includes at least one PEG-Phospholipid conjugated molecule, cholesterol, and at least one phospholipid.
B · US 10,123,973 B2 · abstract
1.4d) PEG-lipid.
In an embodiment, the invention provides a composition of PEG-PL:STX:RX for delivery of a pharmaceutical agent, comprising a poly(ethylene glycol)-phospholipid (PEG-PL), a sterol (STX), and the pharmaceutical agent (RX), wherein said RX is provided in a deaggregated and substantially micellar phase. In an embodiment, said phospholipid is 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and thereby said PEG-phospholipid is PEG-DSPE, thus PEG-DSPE:STX:RX.
A · US 2010/0210575 A1 · ¶ 8
Disclosed is a liposomal composition for treatment of cancer, which includes at least one PEG-Phospholipid conjugated molecule, cholesterol, and at least one phospholipid.
B · US 10,123,973 B2 · abstract
An empty cell means only that no passage was reproduced there.
Statements in these documents
Thus problems with currently existing formulations of important pharmaceutical agents, including antifungal agents, relate to less than satisfactory aspects of toxicity, drug delivery parameters (including, e.g., controlled release and/or aggregation state), efficacy, compatibility with clinical intravenous fluids, and deficiencies for options of combination antifungal compositions and methods.
A · US 2010/0210575 A1 · ¶ 5
In an embodiment, the invention provides a composition of PEG-PL:STX:RX for delivery of a pharmaceutical agent, comprising a poly(ethylene glycol)-phospholipid (PEG-PL), a sterol (STX), and the pharmaceutical agent (RX), wherein said RX is provided in a deaggregated and substantially micellar phase.
A · US 2010/0210575 A1 · ¶ 8
Therefore, there is a need in the art for the development of new therapeutic agents that selectively act on the target tissue without side effects.
B · US 10,123,973 B2 · ¶ 4
The PEG-phospholipid conjugated molecule can have cytotoxicity that is selective to tumor cells, in other words, a tumor cell specific cytotoxic agent.
B · US 10,123,973 B2 · ¶ 8
Cite aspatent.fyi, US 2026/0355118 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355118/, SHA-256 022f88eee44a2783ca245ab635eb13290e5d83d0c0c58058f0521d98d12f68e3